Welcome to our dedicated page for Abcellera Biologics news (Ticker: ABCL), a resource for investors and traders seeking the latest updates and insights on Abcellera Biologics stock.
AbCellera Biologics Inc. develops antibody-based medicines as a clinical-stage biotechnology company. Its updates center on antibody discovery and development programs in endocrinology, women’s health, immunology, oncology, and other areas, including work on complex targets such as GPCRs and ion channels.
Recurring news themes include clinical disclosures for ABCL635, an antibody therapeutic targeting NK3R for the non-hormonal treatment of moderate-to-severe vasomotor symptoms associated with menopause. Company announcements also cover financial results, earnings-call materials, investor conference participation, platform and manufacturing updates, and patent licensing or litigation-resolution developments.
AbCellera (Nasdaq: ABCL) appointed Dr. Victor Sandor to its Board of Directors as an independent director. He is a medical oncologist with senior leadership experience across multiple biotech and pharma companies.
Dr. Sandor helped secure approvals for several oncology drugs and serves on multiple biotech boards.
AbCellera (Nasdaq: ABCL) reported Q1 2026 results and positive interim Phase 1 data for ABCL635, an NK3R antibody for menopausal vasomotor symptoms.
Revenue was $8.3M, net loss $43.2M ($0.14/share), and total available liquidity about $655M. ABCL635 showed favorable tolerability, no liver toxicity, and biomarker suppression supporting monthly dosing and Phase 2 advancement.
AbCellera (Nasdaq: ABCL) will present at investor conferences in May and June 2026. Scheduled presentations: Bank of America Health Care Conference on May 13, 2026 and Jefferies Global Healthcare Conference on June 4, 2026.
Live audio webcasts and replays will be available via links posted on AbCellera's investor relations website closer to each date.
AbCellera (Nasdaq: ABCL) will disclose interim Phase 1 results for ABCL635 on its Q1 2026 earnings call scheduled for May 11, 2026 at 2:00 p.m. PT (5:00 p.m. ET).
The company said it will present safety, pharmacokinetic, and pharmacodynamic target engagement data for ABCL635, a potential first-in-class NK3R antibody for non-hormonal treatment of moderate-to-severe menopausal vasomotor symptoms. Phase 2 readout is anticipated in Q3 2026.
AbCellera (Nasdaq: ABCL) will report first quarter 2026 financial results on May 11, 2026 and hold an earnings conference call at 2:00 p.m. PT / 5:00 p.m. ET the same day.
A live audio webcast and replay will be available through a link on AbCellera's investor relations website.
AbCellera (Nasdaq: ABCL) reported full-year 2025 results: $75.1M revenue, net loss $146.4M (vs. $162.9M in 2024), and approximately $700M available liquidity. The company advanced programs ABCL635 and ABCL575 into clinical trials, moved two candidates into IND/CTA enabling, and opened a clinical manufacturing facility.
Cumulative partner-initiated program starts rose to 104 and molecules in clinic increased to 19.
AbCellera (Nasdaq: ABCL) will present at three investor conferences in March and April 2026: TD Cowen 46th Annual Health Care Conference on March 4, KeyBanc Capital Markets Healthcare Forum on March 17, and Bloom Burton & Co. Healthcare Investor Conference on April 21–22. A live audio webcast and replay will be posted on the company Investor Relations website closer to each date.
AbCellera (Nasdaq: ABCL) will report full year 2025 financial results on Tuesday, February 24, 2026. The company will host an earnings conference call at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time the same day. A live audio webcast will be accessible via a link on AbCellera's Investor Relations website, and a replay will be available at the same link after the call.
AbCellera (Nasdaq: ABCL) announced dosing of the first patients in the Phase 2 portion of its Phase 1/2 trial of ABCL635, a potential first-in-class non-hormonal therapy for moderate-to-severe vasomotor symptoms (VMS) of menopause. The Phase 2 is a multicenter, randomized, double‑blind, placebo‑controlled Proof-of-Concept study in 80 postmenopausal women. The move to Phase 2 follows an interim review of safety, tolerability, and pharmacodynamic data from Phase 1 healthy volunteers and evidence of high target engagement. With Phase 2 enrollment underway, the company anticipates top-line results for both phases in Q3 2026.
AbCellera (Nasdaq: ABCL) announced a global settlement and patent license agreement with Bruker on December 18, 2025. As part of the deal, Bruker will pay $36 million up front and will make future royalty payments on sales of Bruker's Beacon® Optofluidic platform worldwide through the life of the licensed patents. The agreement resolves the companies' global patent litigation and grants Bruker a license to the covered patents.